Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Brookstone Capital Management

Brookstone Capital Management raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 751.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 127,258 shares of the biopharmaceutical company’s stock after purchasing an additional 112,305 shares during the quarter. Brookstone Capital Management’s holdings in Gilead Sciences were worth $9,322,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in GILD. Etesian Wealth Advisors Inc. boosted its position in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. boosted its position in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares during the period. Revolve Wealth Partners LLC boosted its position in Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 130 shares during the period. Steph & Co. boosted its position in Gilead Sciences by 1.9% in the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after buying an additional 142 shares during the period. Finally, First Affirmative Financial Network boosted its position in Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a research report on Friday, June 14th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research report on Wednesday, April 24th. Finally, Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $83.47.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Gilead Sciences Trading Down 0.7 %

Shares of Gilead Sciences stock opened at $68.83 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company’s 50-day simple moving average is $65.89 and its 200-day simple moving average is $72.75. The firm has a market cap of $85.75 billion, a price-to-earnings ratio of 191.19, a price-to-earnings-growth ratio of 2.95 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the previous year, the business posted $1.37 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.47%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.